Literature DB >> 22564270

[The frequency of embolic risk factors and adequacy of anti-embolic treatment in patients with atrial fibrillation: a single tertiary center experience].

Emir Karaçağlar1, Ilyas Atar, Begüm Yetiş, Hafize Corut, Burcu Ersoy, Kerem Yılmaz, Bülent Ozin, Haldun Müderrisoğlu.   

Abstract

OBJECTIVE: Though atrial fibrillation (AF) is the most common sustained arrhythmia permanently; there is not enough data about the prevalence, frequency of risk factors, and adequacy of anticoagulant therapy. We aimed to investigate the prevalence of AF, the frequency of risk factors, adequacy of anticoagulant therapy in patients who were admitted to our outpatient tertiary cardiology clinic according to current guidelines.
METHODS: Patients, admitted to our Cardiology outpatient clinic between January - June 2010 and had a history of AF were included to the study retrospectively. Patients' demographic findings, clinical AF classification, CHA2DS2VASC scores, treatments the measured INR values in last 12 months retrospectively and the success of anticoagulant therapy were evaluated.
RESULTS: Overall, 432 (9.1%) of 4721 patients had AF. Among them 253 (58.5%) patients were female, mean age was 70.4 years. Permanent AF was the most common type. The most common risk factor was hypertension (71.9%). CHA2DS2VASC score was ≥ 2 in 377 patients (87.2%) and 254 (67.3%) of those patients had absolutely indicated for anticoagulation therapy, were taking warfarin. Sixteen of 37 patients with one risk factor, and 10 of 18 patients without risk factors were also receiving warfarin. Although warfarin was indicated in 123 patients, 36 patients had contraindications, 13 patients refused anticoagulation, and warfarin was stopped in 5 patients because of noncompliance with treatment. 15.9% of patients were not on warfarin although anticoagulation was indicated and no contraindication. 83.5% patients INR levels were between therapeutic ranges.
CONCLUSION: Anticoagulation is applied successfully among an important part of AF patients in our tertiary center, but in a substantial group of patients the guidelines are still not implemented. New, cost-effective, safe, accessible treatments are needed for warfarin contraindicated patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22564270     DOI: 10.5152/akd.2012.123

Source DB:  PubMed          Journal:  Anadolu Kardiyol Derg        ISSN: 1302-8723


  7 in total

Review 1.  The Optimal Treatment For Atrial Fibrillation In Less Developed Countries.

Authors:  Xiaohan Fan; Shu Zhang
Journal:  J Atr Fibrillation       Date:  2014-10-31

Review 2.  Atrial fibrillation: the current epidemic.

Authors:  Carlos A Morillo; Amitava Banerjee; Pablo Perel; David Wood; Xavier Jouven
Journal:  J Geriatr Cardiol       Date:  2017-03       Impact factor: 3.327

3.  New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study.

Authors:  Servet Altay; Özlem Yıldırımtürk; Hüseyin Altuğ Çakmak; Lütfü Aşkın; Ümit Yaşar Sinan; Feyzullah Beşli; Ömer Gedikli; Özge Özden Tok
Journal:  Anatol J Cardiol       Date:  2017-01-17       Impact factor: 1.596

4.  ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study).

Authors:  Özcan Başaran; Osman Beton; Volkan Doğan; Mehmet Tekinalp; Ahmet Çağrı Aykan; Ezgi Kalaycıoğlu; İsmail Bolat; Onur Taşar; Özgen Şafak; Macit Kalçık; Mehmet Yaman; İbrahim Altun; Mustafa Özcan Soylu; Cevat Kırma; Murat Biteker
Journal:  Anatol J Cardiol       Date:  2016-10       Impact factor: 1.596

5.  Impaired quality of life in patients with intermittent atrial fibrillation.

Authors:  Cem Nazlı; Nihan Kahya Eren; Selcen Yakar Tülüce; İdil Gökçen Koçağra Yağız; Barış Kılıçaslan; Uğur Kocabaş
Journal:  Anatol J Cardiol       Date:  2015-07-13       Impact factor: 1.596

6.  Burden and correlates of atrial fibrillation among hypertensive patients attending a tertiary hospital in Tanzania.

Authors:  Smita Bhalia; Pedro Pallangyo; Abuu Dalidali; Saada Salum; Richard Kawajika; Edna Kajuna; Happiness Kusiima; Engerasiya Kifai; Peter Kisenge; Tatizo Waane; Mohamed Janabi
Journal:  BMC Cardiovasc Disord       Date:  2020-05-19       Impact factor: 2.298

7.  The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR.

Authors:  Ahmet Çelik; Servet İzci; Mehmet Ali Kobat; Ahmet Hakan Ateş; Abdülkadir Çakmak; Yasin Çakıllı; Mehmet Birhan Yılmaz; Mehdi Zoghi
Journal:  Anatol J Cardiol       Date:  2015-11-19       Impact factor: 1.596

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.